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ddy Van Schuerbeeck, RN,* Paul Nellens, MD,* Guy R. Heyndrickx, MD, PHD,*
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OBJECTIVES The goal of this study was to test the hypothesis that an abnormal response to beta-adrenergic
stimulation may play a role in the pathophysiology of chest pain in patients with normal
coronary arteries.
BACKGROUND The mechanism of angina-like (AL) chest pain in patients with angiographically normal
coronary arteries remains controversial.
METHODS Fifty-eight patients with AL pain and a normal coronary angiogram underwent dobutamine
echocardiography (DE) to evaluate regional wall motion and intraventricular flow velocities
(IFV). Control patients consisted of 22 matched patients free of angina and coronary artery
disease. Abnormal IFV were defined as dagger-shaped Doppler spectrum 3 m/s.
RESULTS Dobutamine-induced regional wall motion abnormalities did not develop in any of the
patients. An IFV  3 m/s was found in 28 patients (48%) with AL pain but in only 4 (18%)
control patients (p  0.05). In the subgroup of patients with AL pain and IFV 3 m/s,
plasma renin concentration (PRC) was higher as compared with those with IFV 3 m/s (18
 17 pg/ml vs. 9  6 pg/ml, p  0.05). There were no differences in plasma ADR, NADR,
or angiotensin-converting enzyme levels. Fourteen patients with angina and IFV 3
underwent control DE and blood sampling after 6 weeks treatment with 10 mg of bisoprolol.
In these patients, a decrease in IFV (from 3.4  0.35 m/s to 2.46  0.64 m/s, p  0.001)
and a decrease in angina score (from 5.4  1.5 to 0.6  1.4, p  0.001) were observed at
follow-up.
CONCLUSIONS The present data suggest that an exaggerated myocardial response to beta-adrenergic
stimulation plays a role in the mechanisms of chest pain in some patients with normal
coronary arteries. (J Am Coll Cardiol 2005;46:1270–5) © 2005 by the American College
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.06.052of Cardiology Foundation
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rbout 10% to 20% of patients with angina-like (AL) chest
iscomfort undergoing cardiac catheterization present with
ormal coronary angiograms (1,2). Despite a good progno-
is, the persistent AL pain adversely affects their quality of
ife and increases their health care expenses (2,3), and their
linical management remains difficult. The AL pain syn-
rome likely represents a heterogeneous entity that depends
n a variety of coexisting pathophysiologic mechanisms. A
inority of patients meet the criteria of syndrome X with
L pain, normal coronary arteries, and documented signs of
yocardial ischemia at exercise electrocardiogram (4), nu-
lear imaging (5,6), or magnetic resonance imaging (7). The
ymptoms of these patients were ascribed to microvascular
ysfunction (8–10). In many of them, an endothelial
ysfunction was found (11) with decreased nitric oxide
roduction and/or increased endothelin-1 release (12–14),
urther supporting an ischemic origin of the complaints.
owever, several investigators failed to document myocar-
From the *Cardiovascular Centre Aalst and the †Department of Epidemiology,
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ccepted June 9, 2005.ial ischemia and reported preserved myocardial blood flow
nd function in these patients despite stress-induced chest
ain (15,16). Accordingly, the pain was attributed to an
bnormal pain perception (17–19) and enhanced activity of
he sympathetic system (20). Ischemic origin of chest pain
as been further challenged by the presence of preserved
etabolism (21), hyperdynamic contractility at rest (15,22),
r induction of an LV outflow tract obstruction during
obutamine infusion (23), suggesting hyperresponsiveness
o beta-adrenergic stimulation as an underlying pathophys-
ologic mechanism. Therefore, in our study, we tested the
ypothesis that a hyperdynamic response to beta-adrenergic
timulation contributes to the occurrence of AL pain in
atients with normal coronary arteries.
ETHODS
atients. We studied 58 consecutive patients with AL
hest pain and normal coronary arteries. All patients pre-
ented with chest pain on effort of characteristic nature,
ocation, irradiation, and associated symptoms prompting
eferral for cardiac catheterization. Patients with left ven-
ricular (LV) hypertrophy (echocardiographic wall thickness
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xcluded from the study. All patients successively under-
ent clinical evaluation of angina score, coronary angiogra-
hy, dobutamine echocardiography (DE), and biochemical
nalysis. Twenty-two patients free of any cardiac symptoms
erved as control patients. Written informed consent was
btained in all patients in accordance with institutional
uidelines. In addition, patients who were given bisoprolol
ave their oral informed consent.
ngina score. Patients subjectively scored their chest dis-
omfort on a scale from 1 (minimal angina) to 10 (most
evere angina).
oronary angiography. Two experienced angiographers
nterpreted the coronary angiograms. Patients were ex-
luded when a coronary stenosis of more than 30% (as
ssessed by quantitative coronary angiography) was present
n any epicardial segment. In six patients, luminal irregu-
arities (30% diameter stenosis) were visible on the angio-
ram. Pressure-derived fractional flow reserve was larger
han 0.90 in all of them.
obutamine echocardiography (DE). Long-acting ni-
rates and calcium-channel blockers were discontinued at
east 36 h before the DE. The beta-blockers were discon-
inued at least 8 days before DE. The latter was performed
ith a commercially available system (Acuson Sequoia
256, Mountain View, California) in all patients within
2 h after coronary angiography as described elsewhere (24).
obutamine was infused intravenously at incremental dos-
ges of 10, 20, 30, and 40 g·kg1·min1 for 3 min.
arasternal long- and short-axis and apical four- and two-
hamber echocardiographic images were recorded at rest
nd at each stage of the test. The LV regional wall motion,
V end-diastolic diameter, LV end-systolic diameter, frac-
ional shortening, systolic wall thickening of interventricular
eptum, and of posterior wall, contractility index (the ratio
f systolic blood pressure to LV end-systolic volume), as
ell as intraventricular flow velocities (IFV) using high-
ulse repetition frequency Doppler in the LV outflow tract
nd at the midventricular level, were recorded at rest, during
ncremental dosages of dobutamine, and during recovery. A
yperdynamic response was defined as the occurrence of
bnormal IFV characterized by a dagger-shaped Doppler
pectrum 3 m/s (Fig. 1).
iochemical analysis. Plasma renin concentration (PRC),
lasma noradrenaline (NADR) and adrenaline (ADR), as
Abbreviations and Acronyms
ADR  adrenaline
AL  angina-like
DE  dobutamine echocardiography
IFV  intraventricular flow velocities
LV  left ventricle/ventricular
NADR  noradrenaline
PRC  plasma renin concentrationell as angiotensin-converting enzyme activity were deter- pined using commercially available assays. The PRC was
ssessed as a marker of systemic enhancement of beta-
drenergic stimulation. It was determined by solid-phase
wo-site radioimmunometric assay (sampling at rest, in a
upine position). The NADR and ADR were determined
sing high-pressure liquid chromatography. The
ngiotensin-converting enzyme activity was measured by a
olorimetric assay.
ollow-up. Fourteen patients with AL pain and in whom
n IFV 3 m/s developed were treated with bisoprolol 10
g for 6 weeks. At the end of this period, the patients
nderwent a control clinical evaluation with DE and blood
ampling.
tatistical analysis. All data are presented as mean 
tandard deviation for continuous data and as a ratio for
ategorical data. Gaussian distributions of data were tested
sing the Kolmogorov-Smirnov test. An unpaired t test or
onparametric Mann-Whitney U test was used to compare
he results of the patients with and without abnormal flow
elocity and to compare the results of the patients and the
ontrol patients. A paired t test or the nonparametric
ilcoxon matched pairs signed rank sum test was used to
ompare the results of the patients before and after treat-
ent with bisoprolol. The Fisher exact test was used to
ompare categorical data. A multivariate logistic regression
nalysis was used to study multiple risk factors and the risk
f abnormal flow velocities. For all analysis, a p value of
0.05 was considered nonsignificant. All statistical analyses
ere performed with the SPSS/PC 11.5 software (SPSS
nc., Chicago, Illinois).
ESULTS
aseline characteristics. There were no significant differ-
nces in demographics and in risk factors for coronary artery
isease (familial history, hyperlipidemia, diabetes, and
moking habits) between patients and control patients
xcept for hypertension (43% in patients vs. 14% in control
igure 1. Example of a high-pulsed repetition Doppler flow velocity
ecording in the left ventricular outflow tract. Abnormal intraventricular
ow velocities were defined as a dagger-shaped Doppler spectrum 3 m/s.atients, p  0.03). Baseline echocardiographic and Dopp-
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Adrenergic Stimulation and Chest Pain October 4, 2005:1270–5er indices were similar in both groups except for the
aseline IFV (1.18  0.22 in patients vs. 0.96  0.30 in
ontrols, p  0.05, Table 1).
obutamine-induced abnormal flow velocities. Table 2
hows the echocardiographic and Doppler indices during
he peak dose of dobutamine in patients and control
atients. None of them developed dobutamine-induced wall
otion abnormalities nor a systolic anterior motion of the
itral valve. As compared with the baseline values, heart
ate, systolic blood pressure, ejection fraction, fractional
hortening, and peak IFV increased significantly and to the
ame extent during the maximal dosage of dobutamine in
oth patients and control patients. However, the occurrence
f IFV 3 m/s was almost three times as frequent in
atients with AL pain than in control patients (28 of 58 vs.
of 22, respectively, p  0.028) (Fig. 2). These abnormal
ow velocities were located at the midventricular level in all
atients.
able 1. Baseline Characteristics of Patients With AL Chest
ain and of Normal Control Patients
AL Group
(n  58)
Control Patients
(n  22) p Value
ge (y) 61  10 56  14 0.10
ale (%) 48.7 57.1 0.79
R* (beats/min) 69  12 70  14 0.91
BP* (mm Hg) 127  17 128  17 0.52
BP* (mm Hg) 73  9 75  9 0.23
VEDD (mm) 51  5 51  6 0.92
VESD (mm) 31  5 32  6 0.60
VS* (mm) 7.5  1.4 8.3  1.6 0.08
W* (mm) 7.2  1.4 7.7  1.6 0.14
WT IVS* (%) 67  34 48  37 0.05
WT PW (%) 99  41 80  37 0.15
F* (%) 67  9 67  9 0.84
S (%) 38  7 37  7 0.27
FV* (m/s) 1.18  0.22 0.96  0.30 0.03
Tested using the Mann-Whitney U test.
AL  angina-like; DBP  diastolic blood pressure; EF  ejection fraction; FS 
ractional shortening; HR  heart rate; IFV  intraventricular flow velocities; IVS 
nd-diastolic septal wall thickness; LVEDD left ventricular end-diastolic diameter;
VESD  left ventricular end-systolic diameter; PW  end diastolic posterior wall
hickness; SWT IVS systolic wall thickening of interventricular septum; SWT PW
systolic wall thickening of posterior wall; SBP  systolic blood pressure.
able 2. Echo Doppler Indices in Patients With AL Pain and
n Normal Control Patients During the Maximal Dosage of
obutamine
AL Group
(n  58)
Control Patients
(n  22) p Value
R* (beats/min) 129  17 131  13 0.97
BP* (mm Hg) 138  27 147  16 0.16
BP* (mm Hg) 75  12 77  6 0.51
VEDD (mm) 46.9  6.4 46.4  5.4 0.80
VESD (mm) 25.3  4.8 25.9  4.8 0.65
F* (%) 76  8 77  6 0.78
S (%) 45  7 44  8 0.99
FV (m/s) 2.84  1.07 2.49  1.09 0.19
FV 3 m/s (patients) 28 (48%) 4 (18%) 0.021Tested using the Mann-Whitney U test.
Abbreviations as in Table 1. Tatients with normal versus abnormal flow velocities.
linical characteristics and echocardiographic and Doppler
ndices of the patients with AL pain are given in Table 3
ccording to the presence or absence of IFV 3 m/s. The
ngina score as well as the echo-Doppler parameters at rest
ere similar in both groups. Nevertheless, patients with IFV
3 m/s experienced more frequently chest pain during DE
han patients with normal dynamics. In addition, induction
f IFV 3 m/s was associated with a larger decrease in LV
nd-systolic dimension and a larger increase in contractility
ndex during DE. There were no differences in systemic
igure 2. Baseline and dobutamine-induced intraventricular flow velocities
n control patients and in patients with chest pain. AL  angina-like.
able 3. Clinical Characteristics and Echocardiographic Indices
f Patients With AL Chest Pain According to the Presence or
bsence of Abnormal IFV
IFV <3 m/s
(1.95  0.40 m/s,
n  30)
IFV >3 m/s
(3.80  0.66 m/s,
n  28)
p
Value
ngina score* 4.57  2.01 5.25  1.43 0.26
obutamine-induced
AL pain
3/30 (10%) 9/28 (32%) 0.05
rterial hypertension 3/30 (10%) 6/28 (21%) 0.30
R (beats/min)
Rest 69  12 69  12 0.78
Dob 127  17 131  17 0.47
BP (mm Hg)
Rest* 128  19 126  15 0.92
Dob* 139  27 138  27 0.70
BP (mm Hg)
Rest* 74  10 73  8 0.82
Dob* 74  12 75  11 0.42
VEDD (mm)
Rest* 51.3  3.6 49.9  5.5 0.35
Dob 48.1  6.6 45.4  6.0 0.17
VESD (mm)
Rest 31.4  4.6 30.8  6.04 0.66
Dob 27.1  3.8 22.9  4.9 0.001
I (mm Hg/ml)
Rest* 3.61  2.06 4.10  2.17 0.22
Dob 4.76  1.58 7.38  3.77 0.02
S (%)
Rest 39  7 38  6 0.75
Dob 44  5 47  9 0.20
Tested using the Mann-Whitney U test.
CI  contractility index; Dob  at dobutamine infusion; other abbreviations as in
able 1.
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October 4, 2005:1270–5 Adrenergic Stimulation and Chest Painemodynamics at rest as well as during dobutamine therapy
etween both groups.
iochemical analysis. Biochemical parameters of patients
ith and without abnormal flow velocities are shown in
able 4. There were no differences in plasma NADR or
DR levels, nor in plasma angiotensin-converting enzyme
ctivity in both groups. In contrast, patients with IFV 3
/s showed significantly higher PRC than patients with
ormal flow dynamics.
When adjusting for age and gender, the risk of abnormal
FV was five-fold higher in patients with a PRC of more
han 14 pg/ml compared with patients with a PRC of 14
g/ml or lower (adjusted odds ratio, 4.7; 95% confidence
nterval, 1.2 to 18.2). In addition, the risk of abnormal IFV,
hen adjusting for age and gender, was nine-fold higher in
atients with a LV end-systolic diameter during dobut-
mine of 23 mm compared with patients with a LV
nd-systolic diameter during dobutamine of more than 23
m (adjusted odds ratio, 9.05; 95% confidence interval,
.08 to 39.43).
linical follow-up after beta-blocker treatment. Four-
een patients with AL chest pain and IFV 3 m/s received
isoprolol 10 mg daily for 6 weeks. As shown in Figure 3,
he angina score was lower in all but one patient (from 5.4
1.5 to 0.6  1.4, p  0.001). This symptomatic
mprovement was paralleled by a marked decrease in the
able 4. Biochemical Analysis in Patients With AL Pain With
nd Without Abnormal IFV
IFV <3 m/s
(n  30)
IFV >3 m/s
(n  28) p Value
DR* (g/l) 0.11  0.22 0.22  0.28 0.14
ADR* (g/l) 0.60  0.54 0.51  0.42 0.55
CE (U/l) 31  12 37  11 0.15
RC* (pg/ml) 9  6 18  17 0.025
Tested using the Mann-Whitney U test.
ADR  adrenalin; ACE  angiotensin-converting enzyme; IFV  intraventric-
lar flow velocities; NADR  noradrenalin; PRC  plasma renin concentration.
igure 3. Abnormal intraventricular flow velocities and angina score in 14r
atients with angina-like chest pain before and after a treatment with 10
g bisoprolol. IFV  intraventricular flow velocities.xtent of IFV (from 3.4  0.35 m/s to 2.46  0.64 m/s, p
0.001).
ISCUSSION
he present study tested the hypothesis that a hyperdy-
amic response to beta-adrenergic stimulation might con-
ribute to the occurrence of AL pain in patients with normal
oronary arteries. The results of the present study can be
ummarized as follows: 1) The incidence of a hyperdynamic
esponse characterized by dobutamine-induced abnormal
FV was higher in patients with AL chest pain and normal
oronary arteries as compared with control patients. 2)
mong the group of patients with AL pain, dobutamine-
nduced IFV of 3 m/s were associated with a larger
ncrease in contractility index, a larger decrease in LV
nd-systolic dimension, and a higher PRC. 3) The treat-
ent with beta-blockers induced a parallel decrease in
ngina score and in the hypercontractile response of the LV.
echanisms of AL pain in patients with normal coronary
rteries. Patients with AL pain and normal coronary arter-
es represent a heterogeneous clinical entity. Several patho-
hysiologic mechanisms might explain the occurrence of
hest pain in these patients. These mechanisms are not
utually exclusive, they are interacting, and it is likely that
hey often co-exist in the same patients. Previous studies
bserved exercise-induced ST-segment changes, reduced
oronary flow reserve, or myocardial perfusion defects in
any of these patients (5–10). Because the epicardial
rteries were normal, these signs of myocardial ischemia
ere attributed to microvascular dysfunction. These patients
ere also shown to have an impaired endothelium-
ependent and endothelium-independent coronary vasodi-
ation during various vasoactive stimuli (5), which might
ontribute to myocardial ischemia. Nevertheless, the sole
schemic hypothesis has been challenged by the observation
f a normal LV contractile response and the absence of
egional wall motion abnormalities during stress testing
15,22,23).
Second, several studies suggested that an abnormal vis-
eral pain perception might play a role in the pathophysi-
logy of the complaints of these patients. (17,20). However,
t remains speculative whether the pain perception is caused
y increased local cardiac sensitivity or if it is related to a
ore complex interaction between abnormal processing of
ociceptive stimuli from the periphery to the central nervous
ystem and inappropriate feedback to heart or neighboring
rgans (17). The current study cannot elucidate the exact
rigin of the pain.
Third, some data suggest an increased sympathetic activ-
ty in patients with AL pain and normal coronary arteries. A
arge proportion of these patients (75%) seems to have an
ltered sympathovagal balance with regional abnormalities
n 123I-metaiodobenzylguanidine (norepinephrine analog)
ptake and enhanced adrenergic drive (19). Other studies
eported increased LV contractility and exaggerated hemo-
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Adrenergic Stimulation and Chest Pain October 4, 2005:1270–5ynamic response to exercise and increased baseline LV
ontractility (22,23). Tousoulis et al. (22) observed resting
V hypercontractility in approximately one-third of pa-
ients with chest pain, normal coronary angiograms, and a
ositive exercise test result. Similarly, Christiaens et al. (23)
bserved that a dynamic LV obstruction is common during
E in patients with AL pain without epicardial coronary
rtery disease. These observations raised the hypothesis that
n adrenergic hyperdynamic response might contribute to
he occurrence of AL chest pain in these patients. In our
tudy, a higher PRC was found in patients with LV
ypercontractility, whereas the levels of ADR and NADR
id not differ. This finding does not unequivocally confirm
nhanced beta-adrenergic myocardial responsiveness, but
ather may relate to a systemic phenomenon.
yperdynamic contractile response and abnormal flow
elocities in AL pain. Consistent with earlier observations
25–27), we observed dobutamine-induced abnormal flow
elocities in 18% of normal individuals. In contrast, in
atients with AL pain and normal coronary arteries, abnor-
al IFV during a dobutamine stress test were observed in
pproximately 50% of patients. These proportions obviously
epend on the cut-off value used. There is no consensus
bout the exact limit above which the velocities in the LV
utflow tract should be considered abnormal. The dagger-
haped (late-peaking) aspect of the flow velocity pattern
eems more important than the actual value of the peak
elocity. The present study suggests that abnormal flow
elocities and underlying cavity squeezing are not related to
ifferent baseline hemodynamics or to particular morpho-
ogic factors but rather to a hyperdynamic response to
eta-adrenergic stimulation. Indeed, LV dimensions and
orphology were similar in patients and in normal individ-
als. In addition, patients with abnormal flow velocities
ere characterized by the presence of higher baseline PRC.
he beta-adrenergic signaling pathway closely controls
atient renin release, and its higher plasma levels for similar
evels of ADR and NADR are likely to reflect a higher
ystemic adrenergic sensitivity in patients with dobutamine-
nduced abnormal flow velocities. Finally, treatment with
eta-adrenergic blockers induced a marked parallel decrease
n dobutamine-induced abnormal flow velocities and AL
hest pain. These observations are consistent with myocar-
ial hypersensitivity to beta-adrenergic stimulation.
Our data do not allow us to address the molecular basis of
he myocardial hypersensitivity. Myocardial effects of do-
utamine are primarily mediated by the beta-1 adrenergic
eceptor, and several genetic variations in the receptor
unction may underlie the observed hemodynamic response.
f note, arginine switch at codon 389 was recently de-
cribed to induce hyperreactivity of the receptor to various
notropic stimuli (28). Our data also do not exclude the
ormal possibility that a parasympathetic rather than a
ympathetic dysfunction could be the cause of the auto-
omic imbalance. Gulli et al. (29) observed reduced para-
ympathetic tone in two thirds of the patients with AL painnd normal coronary arteries, suggesting also an abnormal
drenergic balance. Taken together, these findings further
orroborate the hypothesis that abnormal adrenergic func-
ion and response to beta-adrenergic stimulation contribute
o AL pain in patients with normal coronary arteries.
tudy limitations. In the present study, a hypercontractile
esponse was elicited by infusion of dobutamine. Although
dobutamine stress test is an accepted alternative to
xercise, it does not entirely simulate hemodynamic condi-
ions during exercise. This may cloud the incidence of
bnormal flow velocities during exercise. Second, the ab-
ence of dobutamine-induced wall motion abnormalities
oes not exclude the formal possibility of perfusion abnor-
alities. It is conceivable that echocardiography may not
etect small localized areas of regional ischemia (30).
everal investigators raised the hypothesis that myocardial
schemia in patients with normal coronary arteries may be
aused by constriction of small vessels characterized by a
atchy distribution. Such patchy distribution may be
asked by the tethering effect of neighboring hyperdynamic
egments, and may be insufficient to cause impairment of a
ontractile function detectable by echocardiography. In this
egard, Lanza et al. (19) showed that abnormal cardiac
drenergic activity, as detected by 123metaiodobenzylguani-
ine myocardial scintigraphy scan, is often associated with
he presence of perfusion defects. This suggests the possi-
ility that higher cardiac adrenergic activity may partially
ontribute to microvascular vasoconstriction detected by
erfusion scintigraphy.
ONCLUSIONS
n exaggerated myocardial response to beta-adrenergic
timulation with LV cavity squeezing might play a role in
he pathophysiology of chest pain in patients with normal
oronary arteries. Further studies are required to decipher
he molecular basis of this adrenergic hyperresponsiveness as
ell as to determine the role of beta-blockers in the
reatment of these patients.
eprint requests and correspondence: Dr. Bernard De Bruyne,
ardiovascular Centre Aalst, Moorselbaan 164, 9300 Aalst, Belgium.
-mail: bernard.de.bruyne@olvz-aalst.be or Dr. Jozef Bartunek,
ozef.bartunek@olvz-aalst.be.
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